Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of subcutaneous daratumumab with bispecific T-cell redirecting antibodies in multiple myeloma
NL-OMON59081Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Mar 2020; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59081.